Código 300290 (Harmonized System 2012 by 6 digits)
2024: US$76.2M, Total Trade Exchange
2024: US$6.05M, International Sales
2024: US$70.1M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) was US$76.2M.
In 2024, the states with the most international sales in Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were Ciudad de México (US$4.95M), Baja California (US$125k), and Jalisco (US$94.2k).
The states with the most international purchases in 2024 were Ciudad de México (US$60.3M), Estado de México (US$4.36M), Jalisco (US$1.96M), Querétaro (US$1.64M), and Baja California (US$661k).
In 2024, the main commercial destinations of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were United States (US$4.15M), Chile (US$573k), Canada (US$336k), Kazakhstan (US$50.3k), and Guatemala (US$23.3k).
The main commercial origins of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) in 2024 were United Kingdom (US$19.5M), Switzerland (US$14.4M), Germany (US$13.8M), United States (US$10.7M), and China (US$3.42M).
In the global context, the main exporting countries of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) in 2022 were United States (US$3.6B), Ireland (US$2.02B), and United Kingdom (US$1.13B). In the same year, the main importing countries of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were United States (US$1.39B), Germany (US$902M), and Ireland (US$831M).
US$76.2M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) in Mexico (including international purchases and sales) was US$76.2M.
The visualizations show the net balance of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025
In March 2025, international sales of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were US$671k, while international purchases reached US$2.73M. The above results in a trade balance of -US$2.06M.
2025-Q1: US$1.53M, International Sales
The visualization shows the quarterly concentration of international sales of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) at state level.
In the first quarter of 2025, international sales were US$1.53M, being the states with the most sales Ciudad de México (US$1.51M), Baja California (US$17.7k), and Jalisco (US$9.32k).
Ciudad de México: US$4.95M, State with the Most International Sales (2024)
United States: US$4.15M, Main commercial destination (2024)
In 2024, the states with the highest international sales in Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were Ciudad de México (US$4.95M), Baja California (US$125k), and Jalisco (US$94.2k).
In 2024, the countries with the most international purchases from Mexico were United States (US$4.15M), Chile (US$573k), Canada (US$336k), Kazakhstan (US$50.3k), and Guatemala (US$23.3k).
Ciudad de México: US$60.3M, State with the Most International Purchases (2024)
United Kingdom: US$19.5M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were Ciudad de México (US$60.3M), Estado de México (US$4.36M), Jalisco (US$1.96M), Querétaro (US$1.64M), and Baja California (US$661k).
The countries with the most international sales to Mexico in 2024 were United Kingdom (US$19.5M), Switzerland (US$14.4M), Germany (US$13.8M), United States (US$10.7M), and China (US$3.42M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were United States (US$3.6B), Ireland (US$2.02B), and United Kingdom (US$1.13B). In the same year, the main importing countries for Human Blood; Animal Blood Prepared for Therapeutic Uses, Prophylactic or Diagnostic; Toxins, Cultures of Microorganisms and Similar Products. (Exc. Yeasts and Vaccines) were United States (US$1.39B), Germany (US$902M), and Ireland (US$831M).